RecruitingNCT05093153
Spanish Registry of Patients With IgM Monoclonal Gammopathies
Studying Waldenström macroglobulinemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fundación Española de Hematología y Hemoterapía
- Enrollment
- 1000 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2030
Study locations (30)
- Hospital de Mérida, Mérida, Badajoz, Spain
- Hospital Son Llatzer, Palma, Balearic Islands, Spain
- Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain
- ICO Badalona - Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
- Hospital Mutua Terrassa, Barcelona, Barcelona, Spain
- Hospital de San Juan Despí Moisès Broggi, Barcelona, Barcelona, Spain
- Hospital Clínic de Barcelona, Barcelona, Barcelona, Spain
- Hospital del Mar, Barcelona, Barcelona, Spain
- Hospital Vall d'Hebron, Barcelona, Barcelona, Spain
- Hospital Sant Joan de Déu de Manresa, Manresa, Barcelona, Spain
- Hospital Parc Taulí, Sabadell, Barcelona, Spain
- Hospital Universitario Reina Sofía, Córdoba, Córdoba, Spain
- Hospital Virgen de las Nieves, Granada, Granada, Spain
- Hospital Universitario Clínico San Cecilio, Granada, Granada, Spain
- Hospital Juan Ramón Jiménez, Huelva, Huelva, Spain
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05093153 on ClinicalTrials.govOther trials for Waldenström macroglobulinemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07387471Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)AbbVie
- RECRUITINGPHASE2NCT05099471Efficacy of Venetoclax in Combination With Rituximab in Waldenström's MacroglobulinemiaChristian Buske
- RECRUITINGPHASE2NCT06561347Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WMMassachusetts General Hospital
- RECRUITINGPHASE2NCT05190705Loncastuximab Tesirine in WMShayna Sarosiek, MD
- ACTIVE NOT RECRUITINGPHASE2NCT04624906Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's MacroglobulinemiaSunnybrook Health Sciences Centre
- ACTIVE NOT RECRUITINGPHASE2NCT04273139Ibrutinib + Venetoclax in Untreated WMDana-Farber Cancer Institute
- RECRUITINGPHASE2, PHASE3NCT04061512Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's MacroglobulinaemiaUniversity College, London
- ACTIVE NOT RECRUITINGPHASE1NCT01209871Vaccine Therapy in Treating Patients With Lymphoplasmacytic LymphomaM.D. Anderson Cancer Center